Overview


According to FutureWise analysis the market for vaccine adjuvants in 2023 is US$ 0.8 billion, and is expected to reach US$ 1.39 billion by 2031 at a CAGR of 7.1%.

Adjuvants are substances that strengthen the immune system's defences against antigens. As a result, adjuvants are used in vaccinations to improve their capacity to produce long-lasting immunity to illnesses. The only adjuvants now deemed feasible for use in humans are aluminium salts and MF59, which are being developed as vaccine adjuvants. Following the creation of new-generation vaccines, research and development for effective vaccine adjuvants is advancing dramatically. Modern vaccinations are less immunogenic, necessitating the use of stronger adjuvants in vaccine formulations. In order to create safer and more effective vaccine adjuvants, which will aid in the expansion of the market, scientists and researchers have invested a substantial amount of money in R D initiatives. The market for vaccine adjuvants is being driven by a number of factors, including increased government funding for research and development, a high incidence of diseases, a growing need for better vaccines, and strategic corporate development actions like mergers, acquisitions, and collaborations. The market's growth is, however, constrained by the adverse effects of adjuvants and the high cost of developing them. Additionally, the expansion of this market is being facilitated by rising markets. A significant element driving the demand for vaccination adjuvants is the rising elderly and obese population. The market for vaccine adjuvants is growing as a result of rising spending on the construction of healthcare facilities. Other undirect factors that will contribute to the development of attractive vaccine adjuvants market growth prospects include technological advancements, innovations in aluminium hydroxide-based adjuvants, and individual disposable income. However, a major obstacle to the expansion of the vaccine adjuvants market would be an unfavourable reimbursement scenario in the developing and underdeveloped economies.

FutureWise Market research has instantiated a report that provides an intricate analysis of Vaccine Adjuvants Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Vaccine Adjuvants Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • SEPPIC
  • SDA BIO
  • Brenntag Biosector
  • SPI Pharma
  • MVP Laboratories
  • Tj Kaiwei
  • Novavax
  • Zhuoyue
  • Aphios
  • GSK

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product Type

  • Pathogen Components
  • Adjuvant Emulsions
  • Particulate Adjuvants
  • Combination Adjuvants
  • Others

By Route of Administration

  • Oral
  • Subcutaneous
  • Intranasal
  • Intramuscular
  • Intradermal
  • Others

By Disease Type

  • Infectious Diseases
  • Cancer
  • Others

By Application

  • Research Applications
  • Commercial Applications

By Region

  • North America
  • Latin America
  • Europe
  • Asia-Pacific
  • Middle East and Africa


  • Tier 1 players- established companies in the market with major market share
  • Tier 2 players
  • New Entrants
  • Emerging players which are growing rapidly

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data points affecting market growth

  • To provide with an exhaustive analysis on the Vaccine Adjuvants Market By Product Type, By Route Of Administration, By Disease Type, By Application and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

 

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Vaccine Adjuvants Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Vaccine Adjuvants Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Vaccine Adjuvants Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Vaccine Adjuvants Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pathogen Components
        2. Adjuvant Emulsions
        3. Particulate Adjuvants
        4. Combination Adjuvants
        5. Others

  • 8.   Vaccine Adjuvants Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Subcutaneous
        3. Intranasal
        4. Intramuscular
        5. Intradermal
        6. Others

  • 9.   Vaccine Adjuvants Market, By Disease Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Infectious Diseases
        2. Cancer
        3. Others

  • 10.   Vaccine Adjuvants Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Research Applications
        2. Commercial Applications

  • 11.   North America Vaccine Adjuvants Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Vaccine Adjuvants Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Vaccine Adjuvants Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Vaccine Adjuvants Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. SEPPIC
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. SDA BIO
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Brenntag Biosector
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. SPI Pharma
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. MVP Laboratories
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Tj Kaiwei
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Novavax
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Zhuoyue
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Aphios
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. GSK
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients